VolitionRX (VNRX) to Release Earnings on Wednesday

Key Points

• VolitionRX (VNRX) will release its Q2 2025 earnings report on August 13th, with analysts predicting a loss of ($0.05) per share and revenue of $0.38 million.
• The company's shares opened at $0.64, showing a 2.7% increase, and it has a market capitalization of $66.55 million.
• VolitionRX specializes in developing blood tests for cancer diagnosis and monitoring, with products like Nu.Q Vet and Capture-PCR aimed at improving early disease detection.

VolitionRX (NYSEAMERICAN:VNRX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect VolitionRX to post earnings of ($0.05) per share and revenue of $0.38 million for the quarter.

VolitionRX Stock Performance

VolitionRX stock traded up $0.00 during mid-day trading on Friday, hitting $0.64. 56,031 shares of the company's stock were exchanged, compared to its average volume of 144,746. VolitionRX has a 1-year low of $0.40 and a 1-year high of $0.94. The business has a 50 day moving average price of $0.69. The firm has a market capitalization of $66.76 million, a PE ratio of -2.38 and a beta of 1.26.

VolitionRX Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.